COMMUNIQUÉS West-GlobeNewswire

PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

02/01/2025 - 22:05

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd [...]

Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference

02/01/2025 - 22:05

REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02/01/2025 - 22:01

PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43 r d Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on [...]

EssilorLuxottica strengthens its presence in the hearing space with the acquisition of an AI-driven tech startup in France

02/01/2025 - 18:00

EssilorLuxottica strengthens its presence in the hearing space with the acquisition of an AI-driven tech startup in France Pulse Audition features technology that can embed AI-based speech enhancement into glasses Paris [...]

EssilorLuxottica se renforce dans le domaine de l'audition avec l'acquisition d'une startup technologique française centrée sur l'IA

02/01/2025 - 18:00

EssilorLuxottica se renforce dans le domaine de l'audition avec l'acquisition d'une startup technologique française centrée sur l'IA Pulse Audition apporte une technologie d'Intelligence Artificielle permettant d’ [...]

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

02/01/2025 - 15:15

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 [...]

NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

02/01/2025 - 15:00

LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

02/01/2025 - 14:45

IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approval SP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Silo [...]

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

02/01/2025 - 14:00

PITTSBURGH, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it [...]

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

02/01/2025 - 14:00

DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the [...]

Lexicon Appoints Scott Coiante as Chief Financial Officer

02/01/2025 - 14:00

THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today [...]

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

02/01/2025 - 14:00

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43 rd Annual J.P. [...]

GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing

02/01/2025 - 14:00

Company today announced a major strategic step forward as it explores new growth avenues Artificial Intelligence (AI) and Quantum Computing industries represent multi-trillion dollar market opportunities 1,2 Company is [...]

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

02/01/2025 - 14:00

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

02/01/2025 - 14:00

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at [...]

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

02/01/2025 - 13:45

Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

02/01/2025 - 13:30

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpox Japan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply [...]

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics

02/01/2025 - 13:00

Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has rapidly identified [...]

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

02/01/2025 - 13:00

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 [...]